EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy

Lea Naomi Eder, Danilo Martinovic iD, Paolo Mazzeo iD, Christina Ganster, Justin Hasenkamp, Julia Thomson, Arne Trummer iD, Detlef Haase, Gerald Wulf

Current Oncology · 2023

DOI: 10.3390/curroncol30010087 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Current Oncology, 2023. Verfasst von Lea Naomi Eder und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, University Medicine Goettingen, 37075 Göttingen, Germany. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype. This case may serve as a paradigmatic example of clonal hematopoietic progression in a patient undergoing CAR-T cell therapy, especially in the context of a TP53-mutated clone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenHumansMaleMiddle AgedAntigens, CD19Cell- and Tissue-Based TherapyClonal HematopoiesisImmunotherapy, AdoptiveRemission InductionTumor Suppressor Protein p53Mutation

Stichwörter der Autor:innen

CAR-T cell therapyclonal evolutionclonal hematopoiesistherapy-related neoplasia

Substanzen

Antigens, CD19Receptors, Chimeric AntigenTP53 protein, humanTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Department of Hematology and Medical Oncology, University Medicine Goettingen, 37075 Göttingen, Germany.
  • Department of Hematology and Oncology, Städtisches Klinikum Braunschweig, 38114 Braunschweig, Germany.

ORCID-Profile: Danilo Martinovic, Paolo Mazzeo, Arne Trummer

Zitieren

APA

Eder, L. N., Martinovic, D., Mazzeo, P., Ganster, C., Hasenkamp, J., Thomson, J., Trummer, A., Haase, D., & Wulf, G. (2023). Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy. Current Oncology. https://doi.org/10.3390/curroncol30010087

Vancouver

Eder LN, Martinovic D, Mazzeo P, Ganster C, Hasenkamp J, Thomson J, et al. Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy. Current Oncology. 2023. doi:10.3390/curroncol30010087

BibTeX
@article{Eder2023,
  author = {Eder, Lea Naomi and Martinovic, Danilo and Mazzeo, Paolo and Ganster, Christina and Hasenkamp, Justin and Thomson, Julia and Trummer, Arne and Haase, Detlef and Wulf, Gerald},
  title = {Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30010087}
}
Kostenlos starten →